228 related articles for article (PubMed ID: 31623855)
1. Current status and limitations of immunotherapy for breast cancer.
Tokumaru Y; Joyce D; Takabe K
Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
[No Abstract] [Full Text] [Related]
2. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
3. Women's cancer: Advancing molecular and immunotherapy.
Dorigo O
Curr Probl Cancer; 2017; 41(1):7. PubMed ID: 28366203
[No Abstract] [Full Text] [Related]
4. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
5. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor Therapy in Breast Cancer.
Santa-Maria CA; Nanda R
J Natl Compr Canc Netw; 2018 Oct; 16(10):1259-1268. PubMed ID: 30323094
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype.
Moehler M
Oncol Res Treat; 2018; 41(5):264-265. PubMed ID: 29705785
[No Abstract] [Full Text] [Related]
8. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
9. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
Front Immunol; 2018; 9():3107. PubMed ID: 30692993
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in the management of bladder cancer: Introduction.
Smith AB
Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic breast cancer: an old histotype but a current therapeutic problem.
Gadaleta-Caldarola G; Nenna R; Lanotte L; Doronzo A; Gadaleta-Caldarola A; Roma I; Lombardi L; Infusino S
Future Oncol; 2021 Mar; 17(8):955-963. PubMed ID: 33538176
[TBL] [Abstract][Full Text] [Related]
13. Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective.
Choi SH; Kim JW; Choi J; Sohn J; Kim SI; Park S; Park HS; Jeong J; Suh CO; Keum KC; Kim YB; Lee IJ
Clin Breast Cancer; 2018 Apr; 18(2):e167-e178. PubMed ID: 28689012
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
15. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
Printz C
Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327
[No Abstract] [Full Text] [Related]
16. Does adjuvant therapy reduce postmetastatic survival?
Fink MK
Ann Oncol; 2019 Aug; 30(8):1184-1188. PubMed ID: 31095301
[No Abstract] [Full Text] [Related]
17. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
19. Development of adaptive immune effector therapies in solid tumors.
Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
[TBL] [Abstract][Full Text] [Related]
20. Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.
Dahn H; Wilke D; Walsh G; Pignol JP
Breast Cancer Res Treat; 2020 Jul; 182(2):411-420. PubMed ID: 32441018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
